Previous 10 | Next 10 |
BEVERLY, Mass., April 16, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report recent academic and pre-clinical research further supports the therapeutic potential of Kevetrin, the Co...
BEVERLY, Mass., April 09, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report that the Company has implemented yield and purity enhancements in the manufacturing of Brilacidin for th...
BEVERLY, Mass., March 28, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, announced today that the European Medicines Agency (EMA) has granted a meeting with the Company’s European subsidiary, IP...
BEVERLY, Mass., March 15, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to inform shareholders that necessary documentation has been completed for the European Medicines Agency (EMA) Ma...
BEVERLY, Mass., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to announce that the Companies Registration Office Ireland has provided notification that the Company’s sub...
BEVERLY, Mass., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report that the U.S. Patent & Trademark Office issued today a new patent to the Company for the treatment o...
Innovation Pharmaceuticals ( OTCQB:IPIX ): Q2 GAAP EPS of -$0.02. Press Release More news on: Innovation Pharmaceuticals Inc., Earnings news and commentary, Healthcare stocks news, ,
BEVERLY, Mass., Feb. 11, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, announces that on February 8, 2019, it filed with the U.S. Securities and Exchange Commission its Quarterly Report on Form 10-Q f...
BEVERLY, Mass., Jan. 31, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, today announces that the Company is establishing a wholly-owned European subsidiary for the purpose of the development of its dru...
Venture Market News for January 22, 2019 KushCo Holdings, Inc. Closes $34,000,000 Registered Direct Offering GARDEN GROVE, Calif., Jan. 22, 2019 (GLOBE NEWSWIRE) -- KushCo Holdings, Inc. (OTCQB: KSHB) (“KushCo” or the “Company”), the parent company of innova...
News, Short Squeeze, Breakout and More Instantly...
Innovation Pharmaceuticals Inc Company Name:
IPIX Stock Symbol:
OTCMKTS Market:
WAKEFIELD, MA, Aug. 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company and minority stakeholder in BT BeaMed Technologies (“BeaMed”), is pleased to provide shareho...
WAKEFIELD, MA, June 21, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced the United States Patent and Trade Office (USPTO), on June 6, 2023, granted a patent, &...
WAKEFIELD, MA, June 05, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company and minority stakeholder in BT BeaMed Technologies (“BeaMed”), is pleased to inform sh...